Skip to main content
Retour
CTNM logo

Contineum Therapeutics, Inc. Class A Common Stock

Qualité des données : 100%
CTNM
NASDAQ Healthcare Biotechnology
13,65 €
▲ 0,37 € (2,79%)
Cap. Boursière : 509,64M
Fourchette du Jour
13,03 € 13,80 €
Fourchette 52 Semaines
3,35 € 16,33 €
Volume
137 766
Moyenne 50J / 200J
13,74 € / 10,26 €
Clôture Précédente
13,28 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (633 pairs)

Métrique Action Médiane du Secteur
P/E -8,5 0,2
P/B 2,0 2,9
ROE % -26,1 3,7
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -55,54M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-26,13%
ROIC-18,96%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,03
Current Ratio27,50
Interest Coverage0,00

Valorisation

P/E Ratio
-8,50
Forward P/EN/A
P/B Ratio1,95
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -59,98M
ROE -26,13% ROA -21,68%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -55,54M
ROIC -18,96% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 27,50
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8,50 Forward P/E N/A
P/B Ratio 1,95 P/S Ratio N/A
PEG Ratio 11,51 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -10,90%
Market Cap 509,64M Enterprise Value 442,28M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 50,00M 0,0 0,0
Net Income -59,98M -42,26M 22,72M -24,25M -29,00M
EPS (Diluted) -2,17 -2,18 0,90 -0,97 -1,15
Gross Profit -323 000,0 -258 000,0 50,00M -329 000,0 0,0
Operating Income -68,06M -50,89M -16,08M -22,72M -28,65M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 276,64M 212,85M 130,39M 50,64M 70,52M
Total Liabilities 15,65M 14,78M 198,32M 11,37M 8,93M
Shareholders' Equity 260,99M 198,07M -67,94M 39,27M 61,59M
Total Debt 8,25M 6,26M 193,19M 5,85M 4,91M
Cash & Equivalents 75,60M 21,94M 15,53M 5,57M 4,63M
Current Assets 267,92M 206,39M 127,71M 48,39M 69,78M
Current Liabilities 9,74M 9,97M 5,48M 7,55M 3,67M